Skin booster (스킨부스터).

Microdroplet injections of a non-volumizing product into the dermis, aimed at improving hydration, elasticity, fine line density, and overall skin quality. Unlike fillers, the point is not to change shape — it's to change tissue behavior.

Rejuran (리쥬란, polynucleotide from salmon DNA) is the flagship Korean product — originally developed for scar healing, now a mass-market skin treatment. Profhilo (hybrid HA) is the Italian gold standard for hydration. Juvelook (PLLA microspheres) stimulates collagen. SkinVive (Juvederm's micro-HA product) is newer. Most clinics offer 2–3 of these.

Typically 3–5 sessions spaced 2–4 weeks apart, followed by maintenance every 4–6 months. Often combined with laser toning or low-fluence picolaser in the same visit.

Small bumps at each injection point for 12–24 hours — longer with some products. Occasional minor bruising. Makeup can usually be applied the next day.

Rejuran: ₩250,000–₩400,000 per session. Profhilo: ₩350,000–₩600,000 per session. Juvelook: ₩300,000–₩500,000 per session. Packages of 3–5 sessions are typically priced 10–20% below single-session totals.

"Which product do you recommend for my specific concern, and why not the others?" A good skin-booster consultation should result in product-level specificity, not a generic menu.

A Korean skin-booster appointment (스킨부스터) is a calm, repetitive sequence rather than a single dramatic procedure. Numbing cream is applied across the treatment zones — typically cheeks, forehead, perioral area, and sometimes the neck — and left under cling film for 25 to 30 minutes. The face goes from warm tingling to a flat, slightly heavy sensation; that is the cue the cream has done its work. The clinician then wipes the skin clean, marks a grid, and begins the injections.

Most Korean dermatologists deliver skin boosters as a series of micro-injections in a regular pattern across each zone — typically 30 to 60 fine punctures per session, sometimes more if the neck or decolletage is included. Some clinics use a manual 30G or 32G needle one bleb at a time; others use a stamp-style multi-needle device or an automated injector that places multiple papules in a single press. Each puncture feels like a small sting followed by mild pressure as the bleb forms. Most patients describe it as tolerable rather than painful, particularly in the cheeks; the upper lip and the area immediately below the eyes are the spots people remember.

Day 0 the face looks visibly bumped — small papules at every injection point, sometimes described as an orange-peel appearance, with mild erythema around each bleb. By 12 to 24 hours the papules have absorbed and the skin looks normal, occasionally with a few pinpoint bruises. Day 3 to 7 most patients see a hydration shift before any structural change. The collagen and elasticity changes that drive the actual outcome appear at week 4 onwards and continue to build across the treatment course. Korean protocols typically run 3 to 4 sessions spaced 2 to 4 weeks apart, with maintenance every 4 to 6 months once the initial course is complete.

Polynucleotide and polydeoxyribonucleotide injectables — the broad family that includes Rejuran (리쥬란) and the wider PDRN (폴리뉴클레오타이드) category — have an unusually long pharmacological track record because the parent molecules were originally developed for wound healing rather than aesthetics. Nothing in this section replaces a clinic-specific consultation, and none of it is medical advice. It is the published evidence as it stands.

On safety profile, a 2017 review of the pharmacological activity and clinical use of PDRN (PMID: 28491036) summarises decades of intramuscular and perilesional use in vascular, orthopaedic, and dermatologic indications, with a consistent picture of low systemic toxicity and locally well-tolerated adverse-event profiles. A 2025 narrative bridging the gap between PDRN and PN nomenclature (PMID: 39858543) restated the same conclusion across the broader DNA-derived biopolymer category. The most common reported adverse events from cosmetic injection are local and transient: persistent papules at the bleb site for longer than 24 hours, occasional bruising, mild erythema, and rare delayed nodules at over-treated areas. Hypersensitivity reactions are uncommon but documented, which is the basis for the standard contraindication discussed below.

On Profhilo (프로필로) and the wider stable hybrid hyaluronic-acid category, a worldwide postmarketing safety assessment of high- and low-molecular-weight hyaluronan complexes (PMID: 32685528) drew on more than 40,000 documented exposures and reported adverse-event rates well below 0.1%, dominated by transient edema, erythema, and injection-site discomfort. A separate Korean-relevant survey of skin-booster practice among 235 board-certified Korean dermatologists (PMID: 38093498) confirmed that polynucleotide injection is now treated as an established, repeatable office procedure in Korea rather than an experimental one, with fine lines and dermal hydration cited as the leading indications.

The two contraindications worth raising at consultation. First, salmon allergy. Rejuran and most PDRN products on the Korean market are derived from purified salmon-DNA fragments. Patients with a known salmon or fish hypersensitivity should disclose it; not every fish-allergic patient reacts, but the clinic should weigh the risk before proceeding. Second, pregnancy and breastfeeding. Manufacturer labels and reputable Korean clinics decline cosmetic skin-booster treatment in both states until after weaning. Active skin infection at the injection site, uncontrolled autoimmune disease, and recent isotretinoin courses are also commonly raised as relative contraindications. Discuss with your dermatologist before booking.

Skin boosters target tissue quality rather than volume or shape. The visible endpoint, when it works, is light reflection — the so-called glass skin (유리피부) appearance Korean clinics describe — underpinned by changes in dermal water binding, collagen density, elastin support, and pore tension. Different products do different things, and a thoughtful Korean consultation should match product to concern rather than offering a single house menu.

Rejuran (리쥬란), the polynucleotide flagship, is positioned as a dermal-regeneration agent: the fragmented salmon DNA chains act as signalling molecules that promote fibroblast activity and slowly remodel the dermal matrix over weeks. Korean dermatologists most often use it for fine lines, scar quality, post-acne textural irregularity, and overall thickness. Profhilo (프로필로) is a stable hybrid of high- and low-molecular-weight hyaluronic acid; its mechanism is bioremodelling — slow release of hyaluronan into the dermis with secondary stimulation of collagen and elastin, producing hydration and firmness rather than volume. Juvelook (쥬베룩) is a hybrid of poly-D,L-lactic acid microspheres suspended in non-cross-linked hyaluronic acid; it adds gentle volumising and longer-term collagen stimulation in one product. SkinVive, the newer micro-droplet hyaluronic-acid product from the Juvederm family, is positioned as a simple slow-release hydration agent, with limited collagen claims. Pure PDRN injectables sit closer to the wound-healing end of the spectrum and are often used post-procedure for repair signalling rather than as standalone aesthetics.

What skin boosters do not do is the more important conversation. They do not volumise the way hyaluronic-acid filler does — a flat cheek will still be flat, a hollow tear trough still hollow. They do not paralyse muscle the way botulinum toxin does, so dynamic forehead lines, glabellar elevens, and crow's feet remain the territory of botox. They do not lift sagging skin; that work belongs to PDO threads, HIFU, Ultherapy, or surgical facelift. They do not prevent or reverse sun damage, and they do not replace the basics of daily SPF, retinoid use, and barrier-respecting skincare. A skin booster that is doing meaningful work sits inside a routine, not outside it.

Published outcome data for skin boosters have grown rapidly since 2020, both for the polynucleotide category and for stable hybrid hyaluronan. The picture is consistent: measurable improvements in hydration, elasticity, fine-line density, and patient-reported satisfaction, with effect sizes that are smaller than filler but durable across repeat sessions.

On polynucleotides, a preliminary prospective randomised study of highly purified polynucleotide versus placebo in moderate-to-severe atrophic acne scars (PMID: 33755110) reported significant improvement in scar depth on Antera 3D imaging and patient-reported satisfaction at one and three months, with no significant adverse events in the active arm. A 2024 case-series and review of polynucleotide-based treatments for facial scars including atrophic and post-traumatic scars (PMID: 39561983), and a 2025 systematic review of polynucleotide effectiveness in esthetic medicine (PMID: 39645667), aggregate the cohort-level data with broadly congruent findings. A dedicated review of polynucleotide HPT for Asian skin regeneration and rejuvenation (PMID: 38371328) discusses Korean and broader Asian-cohort experience specifically.

On PDRN itself, the wound-healing literature underpins the dermatologic case. A systematic review of PDRN effects on wound healing and tissue regeneration (PMID: 32757710) summarises consistent improvements in granulation tissue formation, angiogenesis, and re-epithelialisation across pre-clinical and clinical work. The Italian Squadrito randomised controlled trial of intramuscular and perilesional PDRN in 216 patients with chronic diabetic foot ulcers (PMID: 24483158) reported complete wound closure in 37.3% of the PDRN arm versus 18.9% on placebo at 8 weeks. A Korean prospective randomised trial in non-healing diabetic foot ulcers (PMID: 29076318) demonstrated significant improvements in peripheral tissue oxygenation and histological angiogenesis on day 7, day 14, and day 28 in the PDRN-treated arm, with the same dosing schedule. A 2016 evaluation of PDRN intradermal injection in facial hyperpigmentation (PMID: 27598132) reported clinical improvement of melasma-associated mottling after three sessions in a small cohort, with the proposed mechanism being adenosine A2A receptor signalling rather than direct melanocyte suppression.

On Profhilo, the worldwide postmarketing safety dataset (PMID: 32685528) sits alongside open-label efficacy work in skin laxity, neck roughness, and facial elasticity using cutometer R2, R5, and R7 parameters and the Wrinkle Severity Rating Scale. Patient-reported outcomes have been characterised in Asian and European cohorts. The 2025 narrative consolidating PDRN and PN nomenclature (PMID: 39858543) is the reference framing piece for clinicians comparing the two categories in 2026.

Korean skin boosters are the part of the K-beauty ecosystem that most clearly migrated from clinic into search culture. Rejuran healer, the brand-led shorthand for the original Korean polynucleotide product (리쥬란 힐러), is now one of the highest-growth aesthetic search terms internationally, with UK queries reportedly up around 500% across 2024-2026 cycles. Adjacent commercial-intent terms — Rejuran cost, Rejuran near me, Rejuran London, Rejuran Seoul price, Profhilo vs Rejuran — sit at the same end of the volume curve. PDRN as a category, separated from any specific brand, has shown even steeper growth as a topical and injectable search term, reportedly close to 700% on global trend trackers across the same window. Olive Young (올리브영), the dominant Korean retail beauty chain, now stocks PDRN serums (PDRN 세럼) and ampoules across mass-market price tiers, which is the main route the topical category has reached non-clinical consumers.

Inside Korean clinics, the dominant 2026 pattern is stacking. A typical Gangnam single-visit protocol now combines a fractional radio-frequency or low-fluence laser pass for surface texture, a polynucleotide skin booster injection for dermal regeneration, occasionally a topical or injectable PDRN layer for post-procedure repair, and an exosome topical or microneedling step (엑소좀) as the newest layer. Each piece carries its own evidence quality: polynucleotide and Profhilo data are strongest, exosome cosmetic data remain early. The aesthetic target across all of these is the glass skin (유리피부) endpoint — clear, evenly hydrated, light-reflecting skin — rather than visible filler shapes or dramatic line erasure. The same target frames the wider Korean skincare routine (한국 스킨케어) approach: hydration first, barrier respect, and surface optics over corrective intervention.

Comparison search queries have also become useful proxies for what international patients actually want to know. Profhilo vs Rejuran is the most common, and the honest answer in 2026 is that they treat overlapping but different concerns: Profhilo for hydration and bioremodelling, Rejuran and the PN family for dermal regeneration and scar quality. Juvelook (쥬베룩), the Korean PDLLA-HA hybrid, has grown sharply as a longer-duration alternative for patients seeking gentle volumising alongside skin-quality improvement. None of these replace a personalised consultation, and none should be selected on search-trend volume alone.

How many sessions do I need? Korean clinics typically recommend an initial course of 3 to 4 sessions spaced 2 to 4 weeks apart, followed by a single maintenance session every 4 to 6 months. The exact number depends on the product, the indication, and your starting skin condition. Discuss the planned course with your provider before paying for a package.

How long does the result last? Most patients see peak results 4 to 8 weeks after the final session of the initial course, with the effect tapering over the following 4 to 6 months in the absence of maintenance. Polynucleotide and PDRN effects are biological rather than volumetric — they fade gradually rather than disappear suddenly.

Is it safe during pregnancy or breastfeeding? No. Manufacturer labels and reputable Korean clinics decline cosmetic skin-booster treatment in pregnancy and during breastfeeding. Treatment is postponed until after weaning. Ask your provider for their written policy.

I'm allergic to salmon — is Rejuran safe for me? Rejuran and most PDRN products on the Korean market are derived from purified salmon DNA. A known salmon or fish allergy is a stated contraindication for most providers; not every fish-allergic patient reacts, but the safer position is to disclose the allergy and discuss alternatives such as Profhilo (hyaluronic acid only) with your dermatologist before booking.

What's the difference between Rejuran and Profhilo? Rejuran is a polynucleotide derived from salmon DNA; its mechanism is dermal regeneration through fibroblast signalling. Profhilo is a stable hybrid of high- and low-molecular-weight hyaluronic acid; its mechanism is bioremodelling and hydration. Many Korean clinics offer both, and some patients use them in alternating courses for different concerns.

Can I see the result immediately? Not really. Day 0 you will see small papules at each injection point and possibly a flushed appearance. The papules absorb within 12 to 24 hours. The actual skin-quality changes appear at week 4 onwards and build across the course. Anyone promising same-day results is selling a different product.

Will I have visible bumps after? Yes, briefly. Each injection point produces a small papule that is visible for 12 to 24 hours, occasionally up to 48 hours with thicker products such as Profhilo. The bumps are part of the protocol, not a complication.

Can I wear makeup the same day? Most Korean clinics advise waiting until the next morning to allow the injection points to seal fully and to reduce the risk of pigment particles entering the puncture sites. Mineral or clean cosmetic-grade makeup the next day is usually fine.

Is it worth it in your 20s? Korean dermatologists routinely treat patients in their mid-to-late 20s with skin boosters, particularly for post-acne textural concerns, dehydration, and early fine lines around the eyes. The honest answer is that whether it is worth it depends on what you are trying to address; for hydration and texture, a structured course can be useful, while for prevention alone, good skincare and SPF still do most of the work.

Can I combine with botox or filler? Yes — combining a skin booster with botulinum toxin and hyaluronic-acid filler in a single visit is a standard Korean protocol. The usual sequence is filler first, then botulinum toxin, then the skin booster. Discuss the specific combination and any additional downtime with your provider in advance.